直腸癌腫瘤標(biāo)志物檢測試劑盒

直腸癌腫瘤標(biāo)志物檢測試劑盒

Rectal Neoplasms Molecular Marker (Ret,FGFR3 and EGFR ) Detection Kit
 
Description: The kit provides a means of performing Rectal Neoplasms detection method based on kinase activity assays. Three targets of molecular marker (Ret, FGFR3 and EGFR) are involved in Rectal Neoplasms. This kit includes Streptavidin Coated Plates and specific Substrate-Peptides (biotinylated peptide substrates) for detection of the activity of Ret, FGFR3 and EGFR which indicate the prognosis of Rectal Neoplasms.
 


Molecular Markers in Rectal Neoplasms

 

Disease	Molecular Marker	Gene ID	Gene Disease Relation
Rectal Neoplasms	RET	5979	marker/mechanism
Rectal Neoplasms	FGFR3	2261	marker/mechanism
Rectal Neoplasms	EGFR	1956	marker/mechanism

 

- Molecular markers for drug discovery and life science research (mechanism).


Peptide Core Sequence: 

Specific Substrate-Peptides for Rectal Neoplasms Molecular Marker

 

Molecular Marker	Substrate-Peptide	Residue	Reaction_Type
RET	Peptides Mix	Tyr-1062	Phosphorylation
FGFR3	Peptides Mix	Tyr-760	Phosphorylation
EGFR	Peptides Mix	Tyr-783	Phosphorylation

 

Label of Substrate-Peptides: Biotinylated.

Quality Control: The substrate peptide was selected using our Rectal Neoplasms Diagnosis Kit. The quality of the biotinylated peptide was evaluated by reverse-phase HPLC and by mass spectrometry.

Storage: 

Store at 4 °C, Avoid Freeze.

Background:

The RET proto-oncogene encodes a receptor tyrosine kinase for members of the glial cell line-derived neurotrophic factor family of extracellular signalling molecules. RET is an abbreviation for "rearranged during transfection", as the DNA sequence of this gene was originally found to be rearranged within a 3T3 fibroblast cell line following its transfection with DNA taken from human lymphoma cells. RET is the receptor for members of the glial cell line-derived neurotrophic factor (GDNF) family of extracellular signalling molecules or ligands (GFLs). Fibroblast growth factor receptor 3 is a protein that in humans is encoded by the FGFR3 gene.[1] FGFR3 has also been designated as CD333 (cluster of differentiation 333). The protein encoded by this gene is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein would consist of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member binds acidic and basic fibroblast growth hormone and plays a role in bone development and maintenance. The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor(EGFR) is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer. New drugs such as IRESSA and Tarceva directly target the EGFR. Patients have been divided into EGFR-positive and EGFR-negative, based upon whether a tissue test shows a mutation. EGFR-positive patients have shown an impressive 60% response rate, which exceeds the response rate for conventional chemotherapy.
 
 
聯(lián)系方式：
拜琺公司： 業(yè)務(wù)手機(jī)：18221844720   電話：021-34315602  郵箱：biopharmsoft@sina.com